Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226835 · ClinicalTrials.gov registry record
Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198
A clinical trial, sponsored by National Eye Institute (NEI).
- Terminated
- Registry status
- 33
- Enrollment target
NCT02226835: Clinical Trial study, sponsored by National Eye Institute (NEI).
NCT02226835 is a clinical trial that was terminated before completion, run by National Eye Institute (NEI). The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02226835 was terminated before completion, sponsored by National Eye Institute (NEI).
- TERMINATED
- Registry status
- 33 participants
- Enrollment target
Study Summary
Background: \- Alzheimer s disease affects the brain and causes memory and thinking problems in older people. Macular degeneration (MD) is an eye condition. It is the leading reason that people over age 55 in the United States lose their central vision. Central vision is important for seeing fine details and for tasks like reading and driving. A feature of Alzheimer s disease is plaques in the brain. A feature of age-related MD is deposits in the retina in the eye. Researchers want to learn more about these diseases and find out if they are related. Objective: \- To see whether there is a relationship between Alzheimer s disease and age-related macular degeneration. Eligibility: \- People with or without Alzheimer s disease enrolled in another study. Participants must have someone to help them take part in this study. Design: * Participants will be screened through the other study. They will have 1 visit. The tests will take about 3 hours. * Participants will answer questions about their medical and eye history. * Participants will have an eye exam to test how well they see. Their eye pressure will be measured and their eye movements will be checked. * Participants will get eye drops to dilate their pupils. Researchers will take pictures of the retina and the inside of the eye. Researchers may measure the thickness of the retina. * Participants will continue to receive care from their regular eye doctor during and after the study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-08-13 |
| Est. Completion | 2017-01-24 |
Why NCT02226835 stopped before completion
NCT02226835 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02226835 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02226835 about?
NCT02226835 is a clinical study titled "Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198". Background: \- Alzheimer s disease affects the brain and causes memory and thinking problems in older people. Macular degeneration (MD) is an eye condition. It is the leading reason that people over age 55 in the United States lose their central vision. Central vision is important for seeing fine d...
What is the current status of trial NCT02226835?
This trial is currently terminated. The enrollment target is 33 participants. The study started on 2014-08-13. Estimated completion is 2017-01-24.
Who is sponsoring clinical trial NCT02226835?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI